Use of thromboxane receptor antagonist in renal diseases and dysfunction.

摘要

The use is described of [1R-[1 alpha (Z),2 beta ,3 beta ,5 alpha ]]-(+)-7-[5-[[(1,1 min -biphenyl)-4-yl]methoxy]-3-hydrox y-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid or a physiologically acceptable salt, solvate or cyclodextrin complex thereof in the manufacture of medicaments for the therapy or prophylaxis of chronic glomerular diseases including glomerulonephritis, lupus nephritis and systemic lupus erythematosus, renal failure, renal hypertension, hepatorenal syndrome, proteinurea (e.g. albuminurea and microalbuminurea), haemolytic uraemic syndrome and renal impairment following ureteral obstruction.